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Pharmacoepidemiology is an evolving area of research and was recognised as a distinct discipline in the early to 
mid-1980’s. An interface between clinical 
epidemiology and pharmacology, pharma-
coepidemiology beneﬁ ts from methodology 
derived through epidemiology to examine 
drug effects in populations. Pharmacoepi-
demiology encompasses themes including 
pharmacovigilance, drug policy, post-mar-
keting assessment of effectiveness and safety 
of medicines, cost-effectiveness and ratio-
nale use of medicines among other themes 
of research.1
There is growing interest in pharmacoep-
idemiology because randomised controlled 
trials (RCTs) used for registration purposes 
are typically underpowered to reveal safety 
signals for rare events. Furthermore, for 
operational or ethical reasons, it may not be 
feasible to conduct RCTs in special popu-
lations such as the very old and the very 
young, and for a duration long enough to 
capture all safety end points. Advances 
in pharmacoepidemiology have not only 
overcome the boundaries of generalisability 
but also extended the time for follow-up to 
study rare adverse events.1
History of data 
collections and 
pharmaco-
epidemiology in 
New Zealand
Prior to national electronic data collec-
tions and registries in New Zealand, there 
was little pooled health data available on a 
national scale to conduct pharmaco-
epidemiological studies. 
Before the Second World War, the 
Department of Statistics was accountable 
for compiling mortality data. The infor-
mation ascertained in death registration 
forms (known as BDM28) was used by 
government for analysis and planning. In 
1948 the responsibility of registering deaths 
was transferred to the Ministry of Health 
(MoH) and the mortality collection was later 
assigned a National Health Index (NHI) by 
MoH in 1988.2 
Registries such as the New Zealand Cancer 
Registry (NZCR) is managed by New Zealand 
Health Information System (NZHIS) and 
achieved a nationwide success of over 
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90% coverage in 1972.2 Health Beneﬁ ts 
Limited (HBL), through the MoH, managed 
procurement and supply-chain data 
before the introduction of Pharmaceutical 
Management Agency Limited (PHARMAC).3 
Roberts and Norris published ﬁ ndings 
based on the HBL data, which showed 
variations and changes in antidepressants 
dispensing in New Zealand between 1993 
and 1997.4 Subsequently, Nishtala and 
colleagues have published several drug utili-
sation studies analysing the pharmaceutical 
collections (Pharms) supplied by PHARMAC.5
Pharmacovigilance in New Zealand
Pharmacovigilance is a unique area of 
pharmacoepidemiology concerning moni-
toring and reporting of adverse effects of 
medicines and therapeutic devices. The New 
Zealand Pharmacovigilance Centre (NZPhvC) 
is the epicentre for monitoring adverse reac-
tions in New Zealand. The NZPhvC currently 
operates two main programmes: (1) Centre 
for Adverse Reactions Monitoring (CARM) 
and (2) Intensive Vaccine Monitoring 
Programme (IVMP).
The Intensive Medicines Monitoring 
Programme (IMMP) based in Dunedin was a 
branch of the CARM from 1977 until 2013.6 
IMMP established cohorts from prescription 
data, collected event information and 
developed a unique methodology known 
as Prescription Event Monitoring (PEM). 
PEM cohorts contained information, 
supplied by pharmacies, from prescrip-
tions for medicines that have been selected 
for monitoring. MoH superintended IMMP 
coordination through CARM, however, 
some dispensing data entries were recorded 
retrospectively and affected collations as 
pharmacists were provided with hand-
written forms to enter information on 
dispensed prescriptions, and these were 
to be returned through pre-paid postage 
envelopes.6 IMMP made several signiﬁ cant 
contributions to pharmacovigilance in New 
Zealand, performing in-depth epidemio-
logical investigations relating to the safe use 
of medicines and introduced programmes 
such as the Medication Error Reporting 
Programme (MERP).7 
New Zealand’s 
national collections
Several national collections held by 
governmental organisations provide 
signiﬁ cant epidemiological data useful 
for population studies. Big data coverage 
in New Zealand comprises a nationwide 
collection of prescription claims or reim-
bursement data, industry-based and 
wholesale or supplier warehouse databases. 
Data holdings can also be medical, hospital 
or administrative records and events or 
disease-based registers. Table 1 displays a 
list of New Zealand databases used in popu-
lation-based research. 
Methodological 
considerations
Pharmacoepidemiologcal studies are 
observational in nature, and hence suffer 
from confounding and bias. In the last few 
decades, advances in pharmacoepidemi-
ology has encouraged novel methods of 
adjusting for confounding and bias.9 In 
New Zealand, studies have progressed from 
examining trends in medicine utilisation to 
using apposite statistical models to examine 
health outcomes such as mortality, hospi-
talisation and use of primary care services. 
Access to advanced statistical software 
has encouraged use of predictive models 
and propensity score matching or inverse 
propensity score weighting, which to some 
extent mimics the process of randomisation 
in retrospective cohort studies. 
In most observational studies, 
confounding variables typically include 
socioeconomic variables, time independent 
(sex, ethnicity etc.) and time varying 
cofounders (frailty etc.) and multi-mor-
bidity.10 Propensity scores (PS) are now 
increasingly being used to ensure distri-
bution of confounding variables is the same 
in the exposed (treated) and the unexposed 
group (untreated). In propensity weighting, 
weights are applied to the exposed (1/PS) 
and the unexposed (1/(1-PS)) so that the 
overall distribution of the PS scores is the 
same in both groups. Individuals with a 
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Table 1: National collections and registers relevant to pharmacoepidemiology research.
Name Alternative 
nomenclature
Brief description
National claims and collections
Mortality collection Mortality 
database
Confirmed deaths managed by the New Zealand Ministry of Health (MoH) and was first assigned Nation-
al Health Index (NHI) in 1988. 
New Zealand Health Information System data 
warehouse
NZHIS Maintains datasets including Mortality data, NMDS, NZCR.
National Minimum Dataset NMDS NMDS is a national collection of public and private hospital discharge information, including coded 
clinical data for inpatients and day patients.
New Zealand Cancer Registry NZCR NZCR provides data for cancer incidence and survival studies, public health research, monitoring screen-
ing programmes and policy formulation.
General Medical Subsidy Claims GMS GMS claim holds information on subsidies paid to reduce consultation cost with general practitioners for 
children under 15 years of age or subsidy/community card holders.
Medicines Monitoring database M2 Medicines and safety data held by New Zealand Medicines and Medical Devices Safety Authority (Med-
safe).
Pharmaceutical Claims Collection (Pharmaceu-
tical Management Agency (PHARMAC) collects 
and manages data through MoH)
Pharms 
Datamart
Holds dispensing data on medicines claims for prescribed dispensings that are subsidised by PHARMAC.
Primary Health Organisation enrolment 
database
PHO Holds individuals’ data for primary healthcare (Primary Care visits).
Laboratory Collection Labs Holds data on laboratory test carried out in individuals. Labs data reporting was enforced from July 
1994. 
National Non-Admitted Patient Collection NNAP Maintains data on non-institutionalised cases in healthcare facilities.
National Maternity Collection NMC Holds data on maternal deliveries.
Programme for the Integration Of Mental 
Health Datamart
PRIMHD Holds data on mental health status of those accessing healthcare.
Intensive Medicines Monitoring Programme 
(Part of New Zealand Pharmacovigilance 
Centre (NZPhvC) or Programme with Centre for 
Adverse Reaction Monitoring (CARM) including 
Prescription Event Monitoring)
IMMP database CARM held dispensing data for signal detection for more than three decades (1977–2013).
Client Claims Processing System CCPS The CCPS holds data which accounts for disability support events in community dwelling older people.
Events and disease-based registers
Births, Deaths and Marriages Register BDM Held by MoH.
Virtual Diabetes Register VDR Specific algorithm is used to extract VDR data from NMDS database.
National Immunisation Register NIR Holds individual level data on immunisation.
National Cervical Screening Programme 
Register 
NCSP Cervical cancer screening database which holds data and some clinical information on females signed 
up to the Programme.
Australian & New Zealand Hip Fracture Register Hip Fracture 
Register
Piloted in New Zealand.
Electronic medical (health) records
Hospital Medical Records HMR A keep of medical records including those prescribed for hospitalised patients.
Medication Error Reporting Programme (MERP) MERP database Online reporting system maintained by NZPhvC which holds core information on the medicine, medica-
tion error and detail characteristics on factors that precipitated the recorded outcome.
Administrative databases
Aotearoa New Zealand Health Tracker ANZHT Administrative data used in research work to estimate prevalence of common public health diseases like 
gout in population studies.
EpiSurv records (maintained by the Institute of 
Environmental Science and Research)
ESR Mandatory reporting of notifiable diseases that have been reported to Medical O icers in the healthcare 
sector.
New Zealand Deprivation (NZDep) dataset NZDep index NZDep index is a composite deprivation score, extracted independently from information contained in 
census data, which compares socioeconomic positions of small area mesh-blocks between 60–110 peo-
ple based on their location within a given time frame. Score of 1 (least deprived) to 10 (most deprived).8
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high PS score have covariates that favour 
the use of the treatment, and lower PS 
scores suggest that individuals are drawn 
away from the treatment. Therefore, in 
order to achieve the covariate-balancing, 
the PS-weighting method is designed to 
weight down data from over-represented 
individuals and vice versa for data from 
under-represented individuals.
Pharmaco-
epidemiological 
studies in New 
Zealand
Drug safety studies
Several drug safety studies have been 
conducted using the routinely collected 
national data in New Zealand, and have 
been able to associate medicine used with 
health outcomes at a population level.
Winnard et al utilised the Aotearoa New 
Zealand Health Tracker (ANZHT) population 
data to examine the overall prevalence of 
gout, and identiﬁ ed a high prevalence in 
the entire Aotearoa New Zealand popu-
lation, particularly among Māori and Paciﬁ c 
people.11 Similarly, a high co-prevalence of 
gout, diabetes and cardiovascular disease 
in the same population was identiﬁ ed in 
a later study.12 A nationwide nested case-
control study by Blank et al used data 
linkage over four years and identiﬁ ed that 
the use of a proton pump inhibitor was 
associated with a signiﬁ cantly increased 
risk of acute interstitial nephritis.13 Another 
nested case-control study using data linkage 
investigated the association of statin and 
risk of rhabdomyolysis and highlighted that 
the absolute risk of rhabdomyolysis in a 
general population of simvastatin users is 
very low.14 In 2009, Mehta et al examined the 
optimal clopidogrel therapy with the help 
of national health databases and concluded 
that clopidogrel coverage following percu-
taneous coronary intervention improved by 
7% across sociodemographic groups after 
funding restrictions ceased.15
The Research in Pharmacoepidemiology 
(RiPE) group,16 has published copious studies 
covering drug safety using Pharms dataset 
and other datasets such as the NMDS, 
Primary Care visits, Mortality collection 
and NZDep index for older individuals aged 
65 years and above. Among these were 
some landmark studies, which examined 
the impact of Drug Burden Index (DBI), 
a measure of exposure to anticholinergic 
and sedative medications, on geriatric 
adverse drug events including falls, and 
another study which compared the haem-
orrhage-risk associated with anticoagulants 
in older New Zealanders on a propensity 
score matched, population-level cohort.17,18 
The later study concluded that the risk of 
any haemorrhage and intracerebral haem-
orrhage was lower in dabigatran users 
compared to warfarin users.18
Drug utilisation studies using 
national health collections data
Literature search in Ovid MEDLINE and 
EMBASE identiﬁ ed 19 studies that have 
recently been published on pharmacoepi-
demiology using national health collections 
data. These studies are listed in Supple-
mentary Table 1 (page 59). In addition to 
these, several other studies have examined 
utilisation patterns of various medicines, 
which can potentially guide future policy 
directions. 
In 2005/6 Norris et al conducted a 
cross-sectional study using dispensing data 
linked with national datasets to investigate 
equity in statin utilisation among different 
ethnic groups and found that in contrast to 
results from other previous studies, statin 
use approximately matched the pattern of 
need.19 Another study on health services 
utilisation by ethnicity variations was 
conducted by Wheeler et al, using the NZHIS 
via the Patient Information Management 
System (PiMS also known as iPM).20 This 
study highlighted the variations in psychi-
atric inpatient representation, diagnosis and 
compulsory treatment across ethnic groups 
and socioeconomic status. Using toxico-
logical and coronial databases between 
2001 and 2005, Gallagher et al concluded 
that restricted access to work-related chem-
icals and stricter prescription/dispensing 
controls for antidepressants such as tricyclic 
antidepressants may reduce self-poisoning 
in New Zealand.21 
In 2001, two studies reported the use of 
HBL data supplied by PHARMAC on subsi-
dised dispensing of antidepressants between 
1993 and 1997, and examined the regional 
differences4 and changes22 in the prescribing 
of antidepressants in New Zealand. The ﬁ rst 
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study concluded that regional differences 
in anti-depressant prescribing are large, 
and later highlighted that the use of newer 
agents was contributing to increased overall 
use of anti-depressant medication and 
government expenditure in New Zealand. 
The earliest direct national estimates of 
diagnosed congestive heart disease prev-
alence (2008), by sociodemographic status 
was undertaken in New Zealand in 2011.23 
Following this, a recent study examined the 
current epidemiological trends of leprosy 
in New Zealand for a 10-year period (2004 
to 2013) to raise awareness among the 
health professional community and used 
the EpiSurv national surveillance database, 
administered by the Institute of Environ-
mental Science and Research (ESR).24
Registry-based studies
Population-level registry-based studies are 
a newer approach to pharmacoepidemio-
logical studies in New Zealand, in particular 
the Cancer Registry. The incidence trends 
for 18 adult cancers, by ethnicity and socio-
economic status was examined and found 
disparities between the different cancers 
among ethnic groups.25 Another recent 
study examined the prevalence of statin 
discontinuation in individuals aged 75 years 
and older with a diagnosis of cancer, in the 
last year of life.10 This study revealed that 
statins are more likely to be discontinued in 
older individuals with a diagnosis of cancer 
compared to those without cancer. This 
association hints at a plausible trend that 
having cancer is a more legitimate reason 
for discontinuing statins compared to other 
life-limiting conditions, knowing that the 
end-of-life is more predictable for indi-
viduals with cancer than individuals with 
other life-threatening diagnoses.
The National Cervical Screening 
Programme Register (NCSP-R) was used to 
identify women aged 20–69 years of age 
with an index high grade cytology report 
from 2009–2011, investigating pre-vacci-
nation benchmark prevalence for Māori 
and non-Māori women, and identiﬁ ed 
long-term effects of vaccination to be similar 
in the two groups.26 Additionally, Grant et 
al identiﬁ ed associations between parental 
intentions and the subsequent timeliness 
of infant immunisation using the National 
Immunisation Register.27
The Virtual Diabetes Register was used to 
compare the prevalence of diagnosed and 
undiagnosed diabetes and prediabetes in 
New Zealand. In this study, the authors have 
summarised and compared regional and 
national diabetes prevalence surveys under-
taken in New Zealand since the late 1960s.28
interRAI (international Resident 
Assessment Instrument)
From 1st July 2015, it has been mandatory 
that all residential care facilities start 
using the suite of health and support needs 
assessment tools known as interRAI, in 
particular the interRAI Long-Term Care 
Facilities Assessment System (LTCF).29 It 
targets people over the age of 65 years 
who require needs assessment for access 
to long-term publicly funded services. A 
recent study highlighted the user expe-
rience of interRAI assessment tools in New 
Zealand and explored clinicians’ percep-
tions and experience of using interRAI 
electronic assessment tools, highlighting 
some barriers that need to be overcome 
prior to adopting the tool.
Challenges and 
opportunities in 
New Zealand for 
pharmaco-
epidemiological 
research 
Challenges
In 2006, Gauld & Goldﬁ nch highlighted 
noteworthy limitations with the New 
Zealand health data collections. Concerns 
were raised regarding the standardisation 
of data collection systems, diﬃ  culties with 
information exchange and insuﬃ  cient gover-
nance of information maintaining systems.30 
While population-based datasets eliminate 
cost and time constraints, completeness 
and validity of the datasets are of a global 
concern. The New Zealand administrative 
databases are frequently utilised, and their 
accuracy and completeness has been tested 
in few observational studies. 
Opportunities
The New Zealand health sector holds and 
maintains rich observational health care 
data that are valuable for evaluation of 
health outcomes. Health care data describe 
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large patient populations and provide prom-
ising research opportunities for proactive, 
longitudinal surveillance of the safety and 
effectiveness of medicines. New Zealand can 
make major contributions to the knowledge 
base of medicines use and health outcomes 
in real-world settings. Appropriate quality 
and relevant data for monitoring health-re-
lated outcomes will enable opportunities 
for pharmacoepidemiological research and 
developments in policies, services, prac-
tices and quality of life for all individuals 
accessing healthcare in New Zealand. 
Conclusions
Pharmacoepidemiology is an evolving 
scientiﬁ c discipline that offers a number of 
advantages to evaluate medication safety 
in a large population for a long period of 
follow-up, with good generalisability. New 
Zealand is well-positioned globally to make 
signiﬁ cant contributions to the knowledge 
base of outcomes on the quality of medicine 
use in real-world settings. There is an 
increased recognition by various stake-
holders, including Medsafe and PHARMAC, 
that a rapid increase in the quantity, diversity 
and accessibility of patient data will provide 
unprecedented opportunities for rapid 
assessment of drug safety, monitoring phar-
maceutical policies, examining healthcare 
utilisation and decision-making relevant 
to all individuals accessing healthcare in 
New Zealand. This viewpoint article high-
lights the scope for methodological advances 
for performing pharmacoepidemiological 
studies in New Zealand. In conclusion, the 
future of pharmacoepidemiology in New 
Zealand requires an integrated development 
of models to capture outcome data, particu-
larly on safety endpoints, and the integration 
of statisticians and epidemiologists on the 
need to improve designs and methodology in 
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this area of study.
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Supplementary Table 1: Summary of studies using claims dataset in New Zealand.
Author, 
year Study design
Setting/ 
participants
Mean (SD) 
age (years)
Study 
duration Outcome(s) studied Conclusion Statistics 
Ndukwe 
et al, 
20151
Open cohort Popula-
tion-based, ≥65 
years (n=9,684)
79.4 (6.6) 3 years Utilisation changes 
measured yearly in DDD/
TOPD by di erent weights 
of Donepezil
Donepezil utilisation 
increased from 5.2 to 8.2 
DDD/TOPD between 2011 
and 2013, while donepezil 
and beta-blockers con-
comitant use decreased 
(17.9% to 5.1%) of total 
users
ANOVA and 
Student t-tests
Ndukwe 
et al, 
20162
Inception cohort Popula-
tion-based, ≥65 
years (n=1,999)
79.5 (6.4) 3 years TTFD (months), adherence 
(VMPR) and persistence 
(by patient visits and 
dispensing’s)
Median TTFD = 12.4±0.6 
months. Adherence (using 
VMPR) was 89.6% for gap 
of ≤31 days. Donepezil 
non-adherents discontin-
ued 2.2 times faster than 
adherents
Survival curves 
and Cox regres-
sion
Ndukwe 
et al, 
20143
Retrospective 
cross-sectional 
study
Popula-
tion-based, ≥65 
years
75.4 (0.1) 9 years Utilisation changes mea-
sured yearly in DDD/DOPY
Utilisation rates and CV 
measures across DHBs. 
Between 2005 and 2013, 
Tairawhiti DHB had the 
widest CV (20.5%)
CV and Gamma 
regression
Ndukwe 
et al, 
20164
Retrospective 
cross-sectional
Popula-
tion-based, ≥65 
years
75.4 (0.1) 9 years Utilisation changes mea-
sured yearly in DDD/TOPD
Increased utilisation (from 
159.4 to 195.3 DDD/TOPD)
Linear regression
Nishtala 
et al, 
20155
Cross-sectional Popula-
tion-based, ≥65 
years
78.1 (7.8) 9 years Utilisation of  PPI Overall PPI utilisation 
showed a 26.7% increase 
from 2005 to 2013
Trend analysis
Nishtala 
et al, 
20146
Population-based 
study
Popula-
tion-based, ≥65 
years
74.7 1 year Impact of DBI on fall-re-
lated hospitalisations, 
GP visits and all-cause 
mortality
Polypharmacy and 
exposure to  DBI drugs are 
independently associated 
with an increased risk of 
fall-related hospitalisa-
tions, frequency of GP 
visits and mortality
Negative bino-
mial regression, 
Survival analyses
Nishtala 
et al, 
20147
Population-based 
study
Popula-
tion-based, ≥75 
years
- - Exploring potentially inap-
propriate medicines use
Potentially inappropriate 
medicines were identified 
in 42.7% of study partic-
ipants
Poisson regres-
sion
Nishtala 
et al, 
20158
Cross-sectional Popula-
tion-based, ≥65 
years
- 9 years Utilisation of  analgesic 
medications
Analgesic utilisation 
increased by 5.44% from 
2005 to 2013
Trend analysis
Nishtala 
et al, 
20159
Cross-sectional Popula-
tion-based, ≥65 
years
- 9 years Prevalence and trends of 
polypharmacy and hyper-
polypharmacy
Polypharmacy and 
hyperpolypharmacy were 
found to be higher in 2013 
compared to 2005 (poly-
pharmacy: 29.5 vs 23.4%, 
p<.001; hyperpolypharma-
cy: 2.1 vs 1.3%, p<.001)
Chi-squared test, 
multinomial 
regression
Nishtala 
et al, 
201610
New user design 
cohort
Popula-
tion-based, ≥65 
years
Warfarin 
cohort: 77.4 
(6.6)
Dabigatran 
cohort  77.3 
(6.4)
6 months Real world bleeding 
risks with warfarin and 
dabigatran
Risk of any haemorrhage 
and intracerebral haemor-
rhage was lower in dabig-
atran users compared to 
warfarin users
Propensity score 
matching, Cox 
regression
Salahu-
deen et 
al, 201511
Population-based 
study
Popula-
tion-based, 
≥65 years  
(n=537,387)
74.7 (7.6) 1 year Anticholinergic scales are 
associated with global 
adverse health outcomes 
such as hospital admis-
sions, falls, length of stay 
and GP visits
Anticholinergic burden 
scores obtained from each 
of the scales were associ-
ated with adverse clinical 
outcomes of interest
Negative binomi-
al regression
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Author, 
year Study design
Setting/ 
participants
Mean (SD) 
age (years)
Study 
duration Outcome(s) studied Conclusion Statistics 
Salahu-
deen et 
al, 201512
Population-based 
study
Popula-
tion-based, ≥65 
years (n=2,248)
79.0 (8) 1 year Predict adverse anticho-
linergic-type events using 
patient characteristics
Anticholinergic burden 
was found to be a 
significant independent 
predictor for developing 
an anticholinergic event
Logistic regres-
sion
Metcalfe 
et al, 
201313
Population-based 
study
Popula-
tion-based, age 
groups; 0–14, 
15–24, 25–44, 
45–64 and ≥65 
years
- 1 year Variations in dispensing of 
specific medication groups 
by ethnicity
Variable but sizeable 
di erences in medicines 
dispensed to Māori 
compared with non-Māori, 
and likely di erences for 
Pasifika populations
Descriptive 
analysis
Metcalfe 
et al, 
201414
Population-based 
study
Popula-
tion-based
Median:  cat-
egory A = 48 
years (30–63)
category E 
= 71 years 
(61–78)
1 year Actual dispensing’s of 
publicly funded blood 
glucose test strips (SMBG) 
according to severity of 
disease
183,000 patients were 
dispensed diabetes 
medicines  during 2011 
and found variations in 
the use of SMBG between 
treatment groups
Descriptive 
analysis
Smith et 
al, 201015
Population-based 
study
Popula-
tion-based—age 
groups; 0–14, 
15–24, 25–34, 
35–44, 45–54, 
55–64, 65–74, 
≥75 years
- 2 years Diabetes prevalence and 
utilisation of healthcare 
services
Substantial di erences in 
the prevalence of diabetes 
and in hospitalisation 
rates by ethnicity
Descriptive 
analysis
Narayan 
et al, 
201316
Retrospective 
cross-sectional 
study
Popula-
tion-based, 
≥65 years 
(n=537,387)
74.7 (7.6) 1 year Anticholinergic exposure 
using anticholinergic drug 
score, drug burden index 
and acetylcholinesterase 
inhibitors
Significant proportion 
of older people are 
exposed to medicines with 
anticholinergic properties, 
including those dispensed 
acetylcholinesterase 
inhibitors
Student t-test
Narayan 
et al, 
201517
Cross-sectional 
study
Popula-
tion-based, 
≥65 years 
(n=537,387)
74.7 (7.6) 1 year Prevalence of PIMs 40.9% of older people 
were prescribed PIMs with 
approximately half dis-
pensed ≥2  PIMs in 2011
Trend analysis
Narayan 
et al, 
201618
Cross-sectional 
study
Popula-
tion-based, ≥65 
years
- 9 years Utilisation of preventive 
medicines from 2005 to 
2013
Utilisation of  selected 
antithrombotics such as 
low-dose aspirin, clopi-
dogrel, dabigatran and 
statins increased over the 
9-year-study period and 
utilisation of dipyridamo-
le, warfarin and bisphos-
phonates decreased
Poisson regres-
sion
Narayan 
et al, 
201519
Cross-sectional 
study
Popula-
tion-based, ≥80 
years
84.9 (4.3) 10 years Utilisation of antihyperten-
sive medicines
75.31% of individuals were 
prescribed one or more 
antihypertensive medi-
cines in 2005, compared 
with 78.75% in 2014
Poisson regres-
sion
ANOVA analysis of variance; CV coe icient of variation; DDD/TOPD defined daily dose per thousand older people per day; DHB District Health Board; DDD/
DOPY defined daily dose per DHB-older population per year; TTFD Time-to-first discontinuation; PPI proton pump inhibitors; DBI drug burden index; VMPR 
variable medication possession ratio; GP general practitioner; PIMs potentially inappropriate medicines.
Supplementary Table 1: Summary of studies using claims dataset in New Zealand (Continued).
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